THE TEAM

Georges RAWADI

Chief Executive Officer
LINKEDINORCID

Georges Rawadi holds a PhD in microbiology from the University of Paris VI (Pierre et Marie Curie) and trained in business administration and management at ESSEC Business School. Forover 25 years, he has held various positions in the pharmaceutical/biotechnology industry as a scientist, drug discovery professional, business development expert and as an executive and entrepreneur supporting biotech companies in their pipeline and financing strategy. Georges is currently a board member of several biotech companies and was CEO of Celyad Oncology and YSOPIA Bioscience. Previously, he was Head of Biotech Studio Development at EureKare and Vice President of Business Development and Intellectual Property, as well as a member of Celyad Oncology's management team. Prior to this, he successfully held various management positions in business development at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis, and led consulting assignments in the development of strategic alliances.

Ana HENNINO

PhD Chief Scientific Officer Co-founder
LINKEDINORCID

Ana Hennino is at the origin of the project, she completed her PhD as an ENS student in Immunology at the INSERM in Lyon in 2001. She developed during PhD studies expertise in molecular mechanisms involved in apoptosis in B cell compartment and identified c-FLIP as a key regulator of the apoptosis of B cells in the germinal center.

Through her post-doctoral studies in the field of immunology of allergy she demonstrated an important role of the CD8+ T cell response at the initiation of the skin-allergic immune response. Since 2014, her research in CancerResearch Center Lyon focuses on the regulation of the immune response by the stromal compartment in the context of autoimmunity and cancer.

Karine AGUERA

Chief Development Officer
LINKEDINORCID

Karine is Program Director. Karine has worked for more than 15 years in the field of biotechnology in project management. She oversaw all the coordination of a major program involving the regulatory authorities, and the medical, pharmaceutical, quality control and R&D teams.

She likes to work cross-functionally with teams from different professional cultures, both internally and externally. Her rigor and her ability to gather information, to mobilize stakeholders, to meet deadlines are decisive for StromaCare where she will be in charge of all the management of the development project of our Lead as well as the editorial parts R&D and toxicity of the regulatory files.

Prof. Eric Raymond , MD, PhD

Medical Advisor
LINKEDINORCID

Eric is an expert in early clinical development and helps Stromacare to fine tune its clinical pathway. He is head of medical oncology at Groupe Hospitalier Paris Saint-Joseph since 2016.

He spent all his carrier in oncology department of prestigious hospitals : Lausanne Hospital, Beaujon Paris Hospital, Saint-Louis Paris Hospital, IGR Paris. He is MD and holds a PhD in Molecular Biology from Pierre et Marie Curie Paris University.

José CORREIA

Chief Quality Officer
LINKEDINORCID

José has spent the last 25 years in biotech companies working, among others, as Director of Quality Assurance, Director of Nonclinical studies, and Director of Clinical studies. He has also led a project up to Phase 3 clinical trial.

He has a broad experience in biological drugs development, from biomanufacturing to clinical trial operations. In its last position, he has set up and managed the Quality Management System for both internal research activities and for GxP subcontracted activities that has allowed to release more than 10 different Investigational Medicinal Products for clinical trials (Phase 1 to Phase 3).

Alexandre DESHIERE

Deputy Chief Scientic Officer
LINKEDINORCID

Alex has worked on various academic preclinical R&D projects in the fields of oncology, immunology and virology in France and Canada. He has acquired expertise in assay development for the screening, functional characterization, and batch release of therapeutic molecules, particularly for humanized monoclonal antibodies.

For the past 6 years, he has worked in the Netherlands as a senior immuno-oncology scientist in a clinical-stage biotechnology company developing innovative bispecific antibodies to treat, and potentially cure patients with diverse forms of cancer.

SCIENTIFIC AND MEDICAL BOARD

Professor Frances BALKWILL

Cancer biologist, PhD Barts Cancer Institute Queen Mary University London
LINKEDIN

Professor Vincenzo BARNABA

Immunologist, MD/PhD Sapienza University Roma , Italy
LINKEDIN

Professor In-San KIM

Cellular biologist, Korean Institute of MD/PhD Science and Technology Seoul, Korea
LINKEDIN

Professor Jean-Yves BLAY

Oncologist, MD, PhD Anticancer Center Léon Bérard, Lyon, France
LINKEDIN

Professor Eric RAYMOND

Oncologist, MD, PhD Paris, France MD, PhD hospital Saint-Joseph Paris France
LINKEDIN

THE STRATEGIC COMMITTEE

Philippe ARCHINARD

PhD Business Angels representative
LINKEDIN

Isabelle BOU ANTOUN

Kreaxi representative
LINKEDIN

Camille DARCISSAC

Pharm D Turenne Capital representative
LINKEDIN

Yann GODFRIN

PhD Historical shareholders
LINKEDIN

Ana HENNINO

PhD Co-founder & CSO
LINKEDIN

Stéphane LEGASTELOIS

PhD Historical shareholders
LINKEDIN

Georges RAWADI

Chief Executive Officer
LINKEDIN

Laurent SACCUCCI

Credit Agricole Création
LINKEDIN